Coppell Advisory Solutions LLC Reduces Position in Abbott Laboratories $ABT

Key Points

• Coppell Advisory Solutions LLC reduced its stock holdings in Abbott Laboratories by 35.2%, now owning 15,497 shares worth approximately $2,022,000.
• Several hedge funds increased their positions in Abbott Laboratories during the 4th quarter, with Jefferies Financial Group raising its holdings by 163.5%.
• Abbott Laboratories reported a quarterly earnings per share (EPS) of $1.26, matching analysts' expectations, while its revenue increased 7.4% compared to the previous year.

Coppell Advisory Solutions LLC reduced its position in Abbott Laboratories (NYSE:ABT - Free Report) by 35.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,497 shares of the healthcare product maker's stock after selling 8,426 shares during the period. Coppell Advisory Solutions LLC's holdings in Abbott Laboratories were worth $2,022,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Meiji Yasuda Asset Management Co Ltd. grew its holdings in Abbott Laboratories by 1.0% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 183,715 shares of the healthcare product maker's stock valued at $24,370,000 after buying an additional 1,800 shares during the last quarter. Canada Post Corp Registered Pension Plan acquired a new stake in Abbott Laboratories during the 1st quarter valued at $18,061,000. Arete Wealth Advisors LLC grew its holdings in Abbott Laboratories by 1.6% during the 1st quarter. Arete Wealth Advisors LLC now owns 22,802 shares of the healthcare product maker's stock valued at $3,025,000 after buying an additional 352 shares during the last quarter. Great Lakes Advisors LLC grew its holdings in Abbott Laboratories by 9.1% during the 1st quarter. Great Lakes Advisors LLC now owns 1,233,576 shares of the healthcare product maker's stock valued at $163,515,000 after buying an additional 103,166 shares during the last quarter. Finally, Voleon Capital Management LP grew its holdings in Abbott Laboratories by 243.4% during the 1st quarter. Voleon Capital Management LP now owns 8,297 shares of the healthcare product maker's stock valued at $1,101,000 after buying an additional 5,881 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on ABT shares. Wells Fargo & Company lowered their target price on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Evercore ISI increased their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Raymond James Financial decreased their price objective on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. BTIG Research decreased their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Finally, Mizuho raised their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 1.9%

Shares of ABT traded down $2.56 during trading hours on Wednesday, hitting $129.39. The stock had a trading volume of 7,392,932 shares, compared to its average volume of 4,846,492. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market cap of $225.20 billion, a P/E ratio of 16.21, a P/E/G ratio of 2.50 and a beta of 0.69. The company's fifty day simple moving average is $130.43 and its 200 day simple moving average is $131.35. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date was Tuesday, July 15th. Abbott Laboratories's payout ratio is currently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.